GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (FRA:2LB) » Definitions » Net Margin %

Iovance Biotherapeutics (FRA:2LB) Net Margin % : -142.67% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Iovance Biotherapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Iovance Biotherapeutics's Net Income for the three months ended in Sep. 2024 was €-75.27 Mil. Iovance Biotherapeutics's Revenue for the three months ended in Sep. 2024 was €52.76 Mil. Therefore, Iovance Biotherapeutics's net margin for the quarter that ended in Sep. 2024 was -142.67%.

The historical rank and industry rank for Iovance Biotherapeutics's Net Margin % or its related term are showing as below:

FRA:2LB' s Net Margin % Range Over the Past 10 Years
Min: -37345.42   Med: -37345.42   Max: -451.26
Current: -451.26


FRA:2LB's Net Margin % is ranked worse than
65.16% of 1019 companies
in the Biotechnology industry
Industry Median: -140.97 vs FRA:2LB: -451.26

Iovance Biotherapeutics Net Margin % Historical Data

The historical data trend for Iovance Biotherapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Net Margin % Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -37,356.15

Iovance Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24,280.87 -24,144.80 -15,796.05 -312.17 -142.67

Competitive Comparison of Iovance Biotherapeutics's Net Margin %

For the Biotechnology subindustry, Iovance Biotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Net Margin % falls into.



Iovance Biotherapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Iovance Biotherapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-407.182/1.09
=-37,356.15 %

Iovance Biotherapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-75.27/52.757
=-142.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Iovance Biotherapeutics  (FRA:2LB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Iovance Biotherapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines